Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced that calderasib (MK-1084), an ...

Merck MRK announced that the FDA has granted Breakthrough Therapy designation to its investigational oral specific KRAS G12C ...

While Summit’s Harmoni-6 results drew a mixed reaction, Eli Lilly’s positive Retvemo data was expanded its potential in ...

A vaccine against ALK-based resistance mutations induces immune responses against all of its targeted antigen in patients ...

Elisrasib monotherapy delivers an ORR of 78.0% and median PFS of 12.4 months in first-line KRAS G12C-mutant NSCLC (n=41) ...

ZEGFROVY® demonstrated superior anti-tumor efficacy compared to platinum-doublet chemotherapy as a first-line treatment for ...

Next generation sequencing (NGS) of malignant effusions and comparison to blood liquid biopsy (ctDNA): A community experience. Celecoxib vs placebo in combination with chemotherapy for non-small cell ...

The U.S. Food and Drug Administration on Friday approved an Amgen Inc drug for non-small cell lung cancer with a specific mutation in a gene known as KRAS in patients whose disease has worsened after ...

Identification of a specific genetic mutation in patients with non-small-cell lung cancer (NSCLC) helps clinicians select the best treatment option. Potential NSCLC patients usually undergo invasive ...

16.0 months median progression-free survival (mPFS) with firmonertinib indicates strong efficacy in first-line patients with EGFR PACC mutant non-small cell lung cancer (NSCLC). Robust central nervous ...

A window of opportunity study for preoperative brigatinib in resectable anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer (NSCLC): WILDERNESS trial. This is an ASCO Meeting Abstract ...

Several reports have noted that individuals with NSCLC whose tumors are documented to contain a mutation in the EGFR receptor have a substantially greater chance of responding to small-molecule ...